Real-World Evidence for Oncology Innovation in EuropeWatch webinarFlatiron Health at ESMO Congress 2025
Connect with us at European Society for Medical Oncology (ESMO) Congress to explore how our comprehensive real-world evidence solutions are accelerating research and advancing patient care worldwide.
Real-world insights. Global impact.
From R&D to post-marketing studies, Flatiron is your trusted partner in delivering oncology evidence across global markets.
At ESMO discover how to:
-
Leverage real-world evidence tailored to your research objectives and regulatory needs.
-
Generate actionable insights across precision medicine, R&D, clinical development, HEOR, RWE, medical affairs, and commercial functions using Flatiron’s AI capabilities and multimodal real-world data.
-
Expand your evidence base globally with our industry-leading real-world data offerings—including linked clinical-multiomics data, Panoramic Data, and multinational datasets from the UK, Germany, and Japan—for deeper insights and broader patient analyses.
Flatiron networking reception
Saturday, 18 October, 2025
19:30-22:30
Join us for an evening of networking, cocktails, and hors d’oeuvres. This is a great opportunity to connect with colleagues, industry peers, and the Flatiron team.
Our research
Read more about our accepted research at this year’s conference.
Treatment duration and subsequent treatments of first-line (1L) CDK4/6i plus aromatase inhibitor (AI) for HR+/HER2- metastatic breast cancer (MBC) in US routine clinical practice
See this research
Track: Breast Cancer, Metastatic
Presentation Number: 523P
Real-world treatment patterns and outcomes in US patients (pts) with neurotrophic tyrosine receptor kinase–positive (NTRK+) solid tumors
See this research
Track: Biomarkers & translational research (agnostic)
Presentation Number: 171P
Featured solutions
The oncology landscape demands robust, timely evidence to support critical business decisions. You need a reliable, experienced partner to work alongside you, helping to build and execute on a customized evidence strategy, and Flatiron delivers the insights you need through our evidence solutions.
Real-World Data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-World Evidence Services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your oncology portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Flatiron Trials
We help sponsors generate prospective evidence through the pragmatic design and execution of interventional trials and prospective observational studies enabled by our oncology-specific CRO services, tech-enabled site network, and purpose-built research technology.
Featured content
Learn more about our multinational real-world data from the UK, Germany, and Japan
Real-World Evidence for Oncology Innovation in EuropeWatch webinar
Ready to unlock global insights for your oncology portfolio?
Leverage Flatiron’s industry-leading oncology solutions, including:
-
Panoramic data with maximum cohort sizes spanning disease settings from our network of >5M patients with cancer
-
Linked clinical-genomic datasets with >78K patients combining Flatiron’s best-in-class longitudinal clinical data and Caris’ industry-leading molecular data
-
Multinational real-world data from the US, UK, Germany and Japan for global evidence generation
-
Full trial execution powered by integrated clinical research technology and end-to-end CRO services
Contact us to learn more about how Flatiron can help develop and deliver more innovative therapies to patients, faster.